6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Submitting institution
-
University of Cambridge
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 12742
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(19)30650-6
- Title of journal
- Lancet
- Article number
- -
- First page
- 2599
- Volume
- 393
- Issue
- 10191
- ISSN
- 1474-547X
- Open access status
- Compliant
- Month of publication
- June
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
32
- Research group(s)
-
-
- Citation count
- 81
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The researcher submitted to REF made a substantial contribution to the organisation of the conduct of the study, and to carrying out the study, and to analysis and interpretation of study data. The researcher also helped draft the output and critiqued the output for important intellectual content.
- Non-English
- No
- English abstract
- -
